AnaCardio
Latest round
- Series B
Last raised
- Sep 2026
Total raised
- $104M
Investors
- 10
About AnaCardio
Based in Stockholm, Sweden, and founded in 2017, AnaCardio AB operates as a clinical-stage biopharmaceutical company that develops medicine for the treatment of heart disease. AnaCardio AB engaged in the development of AC01 for the treatment of heart failure that targets the underlying cause of heart failure: impaired contractility and can be initiated in acute heart failure and transition to chronic oral use. The AC01 drug mimics the peptide and analogously increases contractility ex vivo.
Who invested in AnaCardio
10 investors across 4 rounds
See all investors in AnaCardio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AnaCardio
Who invested in AnaCardio?
AnaCardio has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AnaCardio raised?
AnaCardio has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did AnaCardio last raise money?
AnaCardio's most recent round on record is a Series B, in Sep 2026.
What does AnaCardio do?
Based in Stockholm, Sweden, and founded in 2017, AnaCardio AB operates as a clinical-stage biopharmaceutical company that develops medicine for the treatment of heart disease.
Where is AnaCardio headquartered?
AnaCardio is headquartered in Stockholm, Sweden.
Which VCs invest in companies like AnaCardio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at AnaCardio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like AnaCardio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.